arrow
O

Orla McNally

Royal Women's Hospital
H指数:32
被引数:5,741

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cancer in pregnancy: FIGO Best practice advice and narrative review

妊娠期癌症:FIGO最佳实践建议与叙事性综述

2025-07-240
OAAI
Erratum to ‘Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma’ [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]

勘误:‘Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma’ [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644]

2025-06-110
PRE
Targeting homologous recombination deficiency in uterine leiomyosarcoma

靶向子宫平滑肌肉瘤的同源重组缺陷

2023-05-0410
OAAI
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme
2023-03-312
OAAI
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

同源重组缺陷型终末期高级别浆液性卵巢癌的多组学分析

2023-02-2728
PRE
Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study
2023-01-238
OA
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
2022-12-0135
OA
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
2021-07-2860
OA
The molecular origin and taxonomy of mucinous ovarian carcinoma

卵巢粘液性癌的分子起源和分类

2019-09-02112
OAAI
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
2018-09-28210
OAAI